Recently, the final results of a phase 2 study of eribulin mesylate (1.4 mg/m2) in combination with trastuzumab (8 mg/kg as a loading dose followed by a 6 mg/kg tri-weekly dose) as a first-line therapy for locally recurrent or metastatic HER2+ breast cancer was reported. This evidence concerns the gene ERBB2 and breast cancer.